Download SupplementaryTables

Supplementary Table 1
Reasons for CT-P13 withdrawal due to adverse events
Reason for CT-P13 withdrawal
Unspecified adverse events
Infection
Skin rash
Fatigue
Nausea
Arthralgia
Parestesia
Depression
Myalgia
Oedema
Chest pain or uneasy chest
Headache
Fever or flu-like symptoms
Diarrhea
Unspecified infusion reaction
Sinuitis
Insomnia
Allergic reaction, unspecified
Hypertension
Polycythemia
Psoriasis
Demyelinating disease
Herpes zoster
Hypoglycemia
Dyspnoe
Total
57 events were observed in 37 patients
Number of events
10
6
4
4
3
3
3
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
57
Supplementary Table 2
Baseline demographics and clinical characteristics (by January 2014) of the comparison INX group stratified
by diagnosis
Comparison group of INX treated
patients
Number of patients, n
Women, n (%)
Age, years
Number of comorbidities ≥ 1, n (%)#
Biological treatment number, INX
Concomitant methotrexate, n (%)
Methotrexate dose, mg/week*
Concomitant oral prednisolone, n (%)
In disease remission, n (%)##
Start of INX, year, n
2000-2004
2005-2009
2010-2015
INX dose, mg/kg
INX dose interval, weeks
Prior INX treatment duration, years
Prior INX treatment duration, years, mean
(standard deviation)
RA
PsA
AxSpA
Total
602
418 (70)
62 (49-70)
167 (28)
1 (1-1)
491 (82)
15 (10-20)
57 (9)
343/558 (61)
167
79 (47)
50 (42-60)
42 (25)
1 (1-2)
123 (73)
15 (10-20)
11 (7)
83/154 (54)
352
96 (27)
46 (37-55)
60 (17)
1 (1-2)
118 (34)
12.5 (10-15)
9 (3)
88/319 (28)
1121
593 (53)
55 (44-66)
269 (24)
1 (1-1)
732 (65)
15 (10-20)
77 (7)
514/1031 (50)
119 (20)
299 (50)
184 (31)
3.3 (3.0-4.3)
8 (7-8)
5.8 (3.4-8.4)
6.0 (3.3)
15 (9)
82 (49)
70 (42)
4.8 (3.1-5.2)
8 (6-8)
4.8 (3.1-5.2)
4.8 (3.1)
44 (12)
176 (50)
132 (37)
4.8 (3.6-5.2)
8 (6-8)
5.0 (2.8-7.8)
5.2 (3.1)
178 (16)
557 (50)
386 (35)
3.8 (3.1-5.0)
8 (6-8)
5.3 (3.0-8.0)
5.6 (3.3)
Numbers are medians (interquartile ranges) unless otherwise stated
* Median dose of methotrexate per week among methotrexate treated patients
#: the number of comorbidities was calculated according to the groups in the Charlson comorbidity index excluding
musculoskeletal comorbidity
##: the numbers of patients with available data are shown as denominator. The time window is 32 weeks before/after
January 1st 2014
Abbreviations: RA: rheumatoid arthritis, PsA: psoriatic arthritis, AxSpA: axial spondyloarthritis